African Development Bank provides $15 million loan to Biovac for vaccine production facility
The African Development Bank Group has finalized a loan of up to $15 million for the Biologicals and Vaccines Institute of South Africa Ltd (Biovac). This funding will support the establishment of a new multi-vaccine manufacturing facility in Cape Town, South Africa. The facility is intended to significantly expand Africa's domestic capacity for vaccine production. Specifically, the investment aims to advance the continent's ability to produce cholera vaccines end-to-end. This initiative represents a crucial step towards greater self-sufficiency in vaccine manufacturing within Africa. The agreement was finalized on July 26, 2026. Biovac, based in South Africa, will utilize the loan to enhance its production capabilities. The project is expected to bolster the continent's response to health crises by ensuring a more reliable supply of essential vaccines.
This agreement highlights a strategic investment in Africa's biopharmaceutical infrastructure, aiming to reduce reliance on external vaccine suppliers. By financing a domestic end-to-end production capability, the African Development Bank is fostering regional industrial development and enhancing public health security. The initiative aligns with global trends towards supply chain resilience, particularly relevant in the context of future pandemics. This move could stimulate further investment in African biotechnology and create skilled employment opportunities, while also potentially lowering the long-term cost of vaccines for African nations.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.